Filtered By:
Infectious Disease: Hepatitis
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 32368 results found since Jan 2013.
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Discontinuation of Nucleos(t)ide Analog treatment in HBeAg-Negative Non-Cirrhotic Chronic Hepatitis B Patients: Real-Life Data of 20 Years
CONCLUSION: In resource-limited areas where follow-up of HBsAg or other markers is not possible, nucleos(t)ide analog discontinuation can be considered in patients in the early stage, with low baseline hepatitis B virus DNA and ALT levels, after a long consolidation therapy.PMID:37681268 | DOI:10.5152/tjg.2023.22823
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Bilg ül Mete Sibel Y ıldız Kaya Abdurrahman Kaya Ahmet Furkan Kurt Osman Faruk Bayramlar R ıdvan Karaali İlker İnanç Balkan M ücahit Yemişen Re şat Özaras Ne şe Saltoğlu Fehmi Tabak Source Type: research
Risk of Hepatitis B Virus Reactivation in Patients with Resolved Infection on Therapy with Corticosteroids and Conventional Synthesis Immunosuppressants for Kidney Disease: A Single-Center Analysis of 258 Patients
CONCLUSIONS: Among patients with a previously resolved hepatitis B virus infection on therapy with corticosteroids and conventional synthesis immunosuppressants for kidney disease, hepatitis B virus reactivation was not common and severe, suggesting that universal prophylaxis may not be justified or cost-effective in this clinical setting.PMID:37681265 | DOI:10.5152/tjg.2023.22511
Source: The Turkish Journal of Gastroenterology - September 8, 2023 Category: Gastroenterology Authors: Pingyang Han Ziqiu Wang Zhaohui Wang Source Type: research
Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study
CONCLUSION: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.PMID:37674339 | DOI:10.3947/ic.2023.0045
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Hye Seong Yunsu Choi Kyoung Hwan Ahn Jun Yong Choi Shin-Woo Kim Sang Il Kim Mee-Kyung Kee Bo Youl Choi Boyoung Park Hak Jun Hyun Jin Gu Yoon Ji Yun Noh Hee Jin Cheong Woo Joo Kim Joon Young Song Source Type: research
Do prolonged syndrome of COVID-19 and variants of SARS-COV-2 cause hepatitis of unknown origin in Oaxaca?
Cir Cir. 2023;91(4):583-585. doi: 10.24875/CIRU.22000323.NO ABSTRACTPMID:37677949 | DOI:10.24875/CIRU.22000323
Source: Cirugia y Cirujanos - September 7, 2023 Category: Surgery Authors: Sergio A Ram írez-García Source Type: research
Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study
CONCLUSION: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.PMID:37674339 | DOI:10.3947/ic.2023.0045
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Hye Seong Yunsu Choi Kyoung Hwan Ahn Jun Yong Choi Shin-Woo Kim Sang Il Kim Mee-Kyung Kee Bo Youl Choi Boyoung Park Hak Jun Hyun Jin Gu Yoon Ji Yun Noh Hee Jin Cheong Woo Joo Kim Joon Young Song Source Type: research
Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies
CONCLUSIONS: Eliminating HBV will require interventional strategies to improve diagnostic, linkage-to-care, and treatment coverages. Developing novel therapies will be crucial in further reducing HBV-related mortality and removing HBV as a public health threat.IMPACT AND IMPLICATIONS: This study explores the key developments and optimal intervention strategies needed to achieve WHO hepatitis B elimination targets by 2030 in China. It highlights that China can realise the HBV elimination targets in the incidence by 2025, and by upscaling diagnostic, linkage-to-care, and treatment coverages, up to 2 million lives could poten...
Source: Cancer Control - September 7, 2023 Category: Cancer & Oncology Authors: Rui Li Mingwang Shen Jason J Ong Fuqiang Cui Wenyi Hu Polin Chan Zhuoru Zou Shu Su Hangting Liu Lei Zhang Wai-Kay Seto William C W Wong Source Type: research
